Abstract
Cancer is a genetic disease which progresses from benign to malignant stages through the steady acquisition of genomic mutations in key cell-regulatory genes, namely oncogenes, tumor-suppressors, and stability genes. In many ways cancer is considered as a disease of de-regulated signal transduction. Oncogenic mutations frequently lead to overexpression and/or constitutive activation of signal transduction components, allowing cancer cells to override the controlling mechanisms of signalling networks and acquire the cancer-associated traits known as the six hallmarks of cancer. The molecular chaperone HSP90 is viewed as a key player in the subversion of normal cells toward transformation, since many of its client proteins are linked to signalling pathways, commonly de-regulated during tumorigenesis. Consequently, over the past years HSP90 has emerged as a promising and exciting target for the development of cancer chemotherapeutics and already several HSP90 inhibitors are under clinical evaluation. Recently, a pool of HSP90 was identified at the cell surface, where it was shown to be involved in signalling pathways leading to cell motility and invasion. Independent studies suggest that surface HSP90 could be a promising target for the development of effective anti-metastatic strategies. Thus a need for the development of novel cell-impermeable HSP90 inhibitors is emerging.
Current Signal Transduction Therapy
Title: Extracellular HSP90: An Emerging Target for Cancer Therapy
Volume: 4 Issue: 1
Author(s): Katerina Sidera and Evangelia Patsavoudi
Affiliation:
Abstract: Cancer is a genetic disease which progresses from benign to malignant stages through the steady acquisition of genomic mutations in key cell-regulatory genes, namely oncogenes, tumor-suppressors, and stability genes. In many ways cancer is considered as a disease of de-regulated signal transduction. Oncogenic mutations frequently lead to overexpression and/or constitutive activation of signal transduction components, allowing cancer cells to override the controlling mechanisms of signalling networks and acquire the cancer-associated traits known as the six hallmarks of cancer. The molecular chaperone HSP90 is viewed as a key player in the subversion of normal cells toward transformation, since many of its client proteins are linked to signalling pathways, commonly de-regulated during tumorigenesis. Consequently, over the past years HSP90 has emerged as a promising and exciting target for the development of cancer chemotherapeutics and already several HSP90 inhibitors are under clinical evaluation. Recently, a pool of HSP90 was identified at the cell surface, where it was shown to be involved in signalling pathways leading to cell motility and invasion. Independent studies suggest that surface HSP90 could be a promising target for the development of effective anti-metastatic strategies. Thus a need for the development of novel cell-impermeable HSP90 inhibitors is emerging.
Export Options
About this article
Cite this article as:
Sidera Katerina and Patsavoudi Evangelia, Extracellular HSP90: An Emerging Target for Cancer Therapy, Current Signal Transduction Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157436209787048739
DOI https://dx.doi.org/10.2174/157436209787048739 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Medicinal Plants from Peru: A Review of Plants as Potential Agents Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Keratin-Based Biomaterials for Biomedical Applications
Current Drug Targets Predicting LncRNA-Disease Association Based on Generative Adversarial Network
Current Gene Therapy New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Estrogen Catechols Detection as Biomarkers in Schistosomiasis Induced Cancer and Infertility
Letters in Drug Design & Discovery Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics May Patients with Alcohol Liver Disease Benefit from Herbal Medicines?
Reviews on Recent Clinical Trials Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Tissue Transport of Anti-cancer Drugs
Current Pharmaceutical Design The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics